AltMountain

Alpine ImmunoSciences, L.P.

Seattle, WA · CIK 1628571
Status: no Form D since Dec 2014. Funds file a Form D when they begin selling and amend it each year while the offering continues, so this fund has most likely stopped raising money. It may still be investing, or it may have closed or been dissolved. The details below are from its latest filing, kept here as a record.

Alpine ImmunoSciences, L.P. is a venture capital fund based in Seattle, Washington. Its most recent Form D, filed Dec 24, 2014, reports no sales yet. The minimum investment it accepts from an outside investor is $100,000. It relies on the Section 3(c)(1) exclusion, which limits it to 100 beneficial owners, typically accredited investors. The offering uses Rule 506(b), which does not permit general solicitation. Related persons named in the filing include Mitchell Gold; Alpine BioVentures, GP, LLC.

Total raised
$0Cumulative sales reported on Form D
Investors
0
First sale
—
Minimum investment
$100,000
Who can invest
Accredited investorsSection 3(c)(1): up to 100 beneficial owners
Offering exemption
Rule 506(b)No general advertising
Key people and entities
Mitchell Gold; Alpine BioVentures, GP, LLC
Latest Form D
Dec 24, 2014

From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Returns are not part of SEC filings. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌​​⁠

Questions about Alpine ImmunoSciences, L.P.

What is the minimum investment for Alpine ImmunoSciences, L.P.?

According to its latest Form D, filed Dec 24, 2014, the minimum investment Alpine ImmunoSciences, L.P. accepts from an outside investor is $100,000.

Who can invest in Alpine ImmunoSciences, L.P.?

Alpine ImmunoSciences, L.P. is generally open only to accredited investors, and it may have no more than 100 beneficial owners because it relies on Section 3(c)(1). It uses Rule 506(b), which does not allow general advertising.

How much has Alpine ImmunoSciences, L.P. raised?

Alpine ImmunoSciences, L.P.'s latest Form D, filed Dec 24, 2014, reports no sales yet.

Where is Alpine ImmunoSciences, L.P. based?

Alpine ImmunoSciences, L.P. is based in Seattle, Washington.

Size compared with every venture capital fund

This fund hasn't reported any sales yet.

More venture capital funds in Seattle